AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$WST

Favorite Annette F sold $2.8M of WST

Favorite Annette F (Sr. VP & Chief HR Officer) sold 8,135 shares of WEST PHARMACEUTICAL SERVICES INC (WST) at $340.81 ($2.77M total) across 3 trades on 2026-09-08.

Original reporting
SEC EDGAR · Favorite Annette F
Published Sep 10, 2026, 9:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$WST
Neutral
medium confidence
Mentioned
$WST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WSTNeutralLow
01

Why it matters

The disclosure provides fresh data on insider holdings, useful for short‑term monitoring but unlikely to drive significant price movement.

02

Market read

Primary insider filing; modest size limits market impact.

03

What to watch

Potential upcoming compensation package or tax planning could explain the sale without implying negative outlook.

Relevance 6/10Novelty 6/10Timing: post‑market 2026-09-08

Background

West Pharmaceutical Services (WST) filed a Form 4 reporting an insider sale by a senior executive.

Company-level read

Ticker impact

$WSTNeutralMedium confidence
Context

Senior VP & Chief HR Officer sold 8,135 shares for $2.77M on 2026-09-08, reducing her stake to 16,845 shares.

Expected impact

Potential short-term pressure on the stock, likely limited to a few basis points.

Evidence & confidence

Form 4 is a primary disclosure; however, the transaction amount is relatively small for a mid‑cap, so market reaction is expected to be muted.

Market effects

Sector

Minimal impact on the pharmaceutical services sector; insider sales are routine.

Regional

No discernible regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals and merely personal liquidity needs.

Key entities

  • Company
    West Pharmaceutical Services Inc.

    US‑listed pharmaceutical services provider (ticker WST).

  • Insider
    Favorite Annette F.

    Senior VP & Chief HR Officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

WST insider trading history →

Related articles

JUL 25
$WSTMedAI 8/10

West Pharmaceutical Services, Inc. Q2 2026 Earnings Call Summary

West Pharmaceutical Services reported Q2 2026 results driven by 16% organic growth in Proprietary Products, including a 29% rise in Biologics. High-Value Product components rose to 49% of revenue. Full-year 2026 organic growth guidance was raised to 10% to 11%, with margin expansion expected. SmartDose divestiture and a May cyber incident were cited.

yahoo.com7 min
JUL 24
$WSTHighAI 9/10

West Pharmaceutical Services Q2 Earnings Call Highlights

West Pharmaceutical Services (NYSE:WST) reported Q2 revenue of $872 million, up 13% organically, and adjusted EPS of $2.37, up 29% year over year. The company raised its 2026 outlook to $3.345 billion-$3.38 billion revenue and adjusted EPS of $8.85-$9.05, citing strong high-value product components demand tied to biologics and GLP-1 elastomers, plus margin expansion and buybacks.

yahoo.com6 min